Literature DB >> 10897009

Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer.

D G Bostwick1, E E Alexander, R Singh, A Shan, J Qian, R M Santella, L W Oberley, T Yan, W Zhong, X Jiang, T D Oberley.   

Abstract

BACKGROUND: Oxidative stress results in damage to cellular structures and has been linked to many diseases, including cancer. The authors sought to determine whether the expression of three major antioxidant enzymes, copper-zinc superoxide dismutase (SOD1), manganese superoxide dismutase (SOD2), and catalase, was altered in human prostate carcinoma and its likely precursor, high grade prostatic intraepithelial neoplasia (PIN). The level of reactive oxygen species damage was evaluated by measuring the expression of the DNA adduct 8-hydroxydeoxyguanosine.
METHODS: The authors evaluated the tissue expression of the antioxidant enzymes in prostate carcinoma by immunohistochemistry, immunogold electron microscopy, and enzymatic assay. The polymerase chain reaction was used to amplify and screen tissue specimens for the genes of SOD1, SOD2, and extracellular SOD (SOD3). Matched paraffin embedded tissue sections were evaluated by RNA in situ hybridization for expression of SOD1 and immunohistochemically for the DNA adduct 8-hydroxydeoxyguanosine.
RESULTS: All prostatic tissues, including cancer, displayed immunoreactivity for the three antioxidant enzymes in epithelial cells, with no staining of the stroma, inflammatory cells, or endothelial cells. The number of immunoreactive cells was greater in benign epithelium than in PIN and cancer for each enzyme. The mean percentage and intensity of immunoreactive cells was greatest for SOD2, intermediate for SOD1, and lower for catalase. Staining in cancer was heterogeneous. Immunogold ultrasound studies revealed strong mitochondrial labeling for SOD2, which was greater in benign epithelium than in cancer; SOD1 labeling was invariably weaker, with nuclear labeling in benign epithelium and cytoplasmic labeling in cancer cells. There was no difference in enzyme activity for the three antioxidant enzymes between benign epithelium and cancer. No mutations were found in the 5 exons of SOD1, 5 exons of SOD2, and 3 exons of SOD3, except for 3 of 20 cases with polymorphisms for exon 3 of SOD1. Intense nuclear immunoreactivity for 8-hydroxydeoxyguanosine was present in fewer than 3% of epithelial cells, with no apparent differences among benign epithelium, PIN, and cancer.
CONCLUSIONS: SOD1, SOD2, and catalase had lower expression in PIN and prostate carcinoma than in benign epithelium. The number of immunoreactive cells in PIN was similar to cancer, indicating that these are closely related. Enzyme activities were variable, with no difference between benign epithelial cells and cancer, although this lack of change in enzyme activity could have been due to the presence of contaminating benign cells within the cancer specimens. The results of reactive oxygen species damage were found only in the epithelium and not in the stroma. Expression of the DNA adduct 8-hydroxydeoxyguanosine was present in fewer than 3% of cells, with no apparent differences among benign epithelium, PIN, and cancer. These findings suggest that oxidative stress is an early event in carcinogenesis. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897009

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  82 in total

1.  Oxidative damage and cancer.

Authors:  Terry D Oberley
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

2.  Superoxide dismutase 1 knockdown induces oxidative stress and DNA methylation loss in the prostate.

Authors:  Sachin S Bhusari; Joseph R Dobosy; Vivian Fu; Nima Almassi; Terry Oberley; David F Jarrard
Journal:  Epigenetics       Date:  2010-07-01       Impact factor: 4.528

3.  Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth.

Authors:  Neville N C Tam; Ying Gao; Yuet-Kin Leung; Shuk-Mei Ho
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

4.  Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells.

Authors:  Farideh Mehraein-Ghomi; Hirak S Basu; Dawn R Church; F Michael Hoffmann; George Wilding
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

5.  Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer.

Authors:  Daniel A Barocas; Saundra Motley; Michael S Cookson; Sam S Chang; David F Penson; Qi Dai; Ginger Milne; L Jackson Roberts; Jason Morrow; Raoul S Concepcion; Joseph A Smith; Jay H Fowke
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

6.  Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat.

Authors:  Neville N C Tam; Irwin Leav; Shuk-Mei Ho
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 7.  Redox-modulated phenomena and radiation therapy: the central role of superoxide dismutases.

Authors:  Aaron K Holley; Lu Miao; Daret K St Clair; William H St Clair
Journal:  Antioxid Redox Signal       Date:  2014-02-14       Impact factor: 8.401

Review 8.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

9.  Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study.

Authors:  Ilir Agalliu; Erika M Kwon; Claudia A Salinas; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Causes Control       Date:  2009-11-10       Impact factor: 2.506

10.  Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.

Authors:  Amjad P Khan; Laila M Poisson; Vadiraja B Bhat; Damian Fermin; Rong Zhao; Shanker Kalyana-Sundaram; George Michailidis; Alexey I Nesvizhskii; Gilbert S Omenn; Arul M Chinnaiyan; Arun Sreekumar
Journal:  Mol Cell Proteomics       Date:  2009-11-09       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.